Speeding vaccine development with advanced analytics

Having immediate access to wide ranging resources of data can help speed the COVID-19 vaccine development process COVID-19 is a novel coronavirus, and the big unique challenge is not only is it a novel pathogen in humans, but many of the technologies being pursued for treatment are relatively novel, as well. No RNA vaccines have yet been approved by the FDA, so while vaccine developers are moving as quickly as possible, the process still must be very thorough. A lot of information is being published online through research studies, drugs and vaccines across stages of development, business events and clinical trials and everyone has their eye on the proverbial finish line. In the first week of March, more than 500 research papers were published as opposed to 200 for the whole month of February. According to Signals Analytics, this comes on top of more than 151 drugs that are being developed, 376...